Personalized Medicine Needs Enlightened Regulation To Realize Its Potential
Keywords:biopharmaceuticals, personalized medicine, precision medicine, FDA, regulation, pharmaceuticals, drugs,
Precision, or personalized, medicine, reflects that treatments -- especially those using biopharmaceuticals -- are gradually shifting from a relatively imprecise "one size fits all" approach to a more personalized one, so that patients can be matched to the best therapy based on their genetic makeup and other predictive factors. However, for the pharmaceutical industry, it could be a double-edged sword. On the one hand, it could diminish the number of patients required to demonstrate efficacy in clinical trials, but on the other, it might narrow the approved labeling indications (uses), once the FDA allows the drug to be marketed. Moreover, if regulators require huge safety studies, that could offset the advantage of being able to show efficacy with smaller numbers of patients.
Unless specified by prior arrangement, the author agrees to the following terms and assurances:
- For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
- I/we further give to the following assurances
- I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
- I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
- To the best of my/our knowledge, all the facts in the contribution are true and accurate;
- The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
- Nothing in the contribution is obscene or libellous;
- Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
- I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).